Diagnostics
CardioDx aims for $92M IPO
California molecular diagnostics company CardioDx unveiled new details of its initial public offering, slated to raise $92 million through shares priced at $14-$16 apiece.
Once the IPO launches, CardioDx will trade on the Nasdaq stock market under the symbol "CDX."
CardioDx IPO may fetch $86.3 million
CardioDx is planning something big, although it hasn’t released the full details of its upcoming initial public offering. The Palo Alto, Calif.-based genetic testing company filed preliminary documents for a maximum aggregate offering of up to $86.3 million.
CardioDx hasn’t yet released details of the offering, so the number of shares and individual pricing remains a mystery, but the company has laid out its plans for how it’ll spend the money it hopes to raise.
We have a $1,000 genome. Now what?
By Tom Ulrich
The Human Genome Project’s push to completely sequence the human genome ran a tab of roughly $2.7 billion and required the efforts of 20 research centers around the world using rooms full of equipment.
Report: Private equity giants vie for Johnson & Johnson’s Ortho Clinical Diagnostics biz
PE shop KKR spends $1.7B on 80% stake in Panasonic Health
The $13 test that saved my baby’s life. Why isn’t it required for every newborn?
by Michael Grabell, ProPublica
Nanosphere closes $30M offering
Nanosphere (NSDQ:NSPH) pulled down $30.2 million in a public offering of some 17.3 million shares, including a substantial over-allotment snapped up by the offering’s underwriters.
Nanosphere prices $26M offering | Wall Street Beat
Nanosphere (NSDQ:NSPH) said it priced a public offering of 15 million shares at $1.75 apiece, aiming to drum up a minimum of $26.3 million for its molecular diagnostics technology.
American Cancer Society CMO: Money-driven hospitals push for dangerous tests
Routine screening has been touted as the most effective way to stem cancer deaths, but it may instead put patients in harm’s way, according to American Cancer Society chief medical officer Dr. Otis Brawley. Speaking at a seminar last week, Brawley warned that hospitals recommending regular screening may be looking out for their profits rather than their patients.
T2 Biosystems launches sepsis trial
T2 Biosystems said it’s launched a clinical trial of its MR-based test for a fungus that’s a common cause of deadly hospital-acquired infections.
The Lexington, Mass.-based company said it plans to use the study results to back a regulatory submission for the T2Candida test for the Candida fungus, estimated to cause some 100,000 cases of candidemia each year in the U.S.